218 related articles for article (PubMed ID: 9716152)
1. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity.
Salemink I; Franssen J; Willems GM; Hemker HC; Li A; Wun TC; Lindhout T
Thromb Haemost; 1998 Aug; 80(2):273-80. PubMed ID: 9716152
[TBL] [Abstract][Full Text] [Related]
2. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
Iakhiaev A; Ruf W; Rao LV
Thromb Haemost; 2001 Mar; 85(3):458-63. PubMed ID: 11307815
[TBL] [Abstract][Full Text] [Related]
3. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
Cunningham AC; Hasty KA; Enghild JJ; Mast AE
Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418
[TBL] [Abstract][Full Text] [Related]
5. Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes.
Willems GM; Janssen MP; Salemink I; Wun TC; Lindhout T
Biochemistry; 1998 Mar; 37(10):3321-8. PubMed ID: 9521652
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
[TBL] [Abstract][Full Text] [Related]
7. The importance of the binding of factor Xa to phospholipids in the inhibitory mechanism of tissue factor pathway inhibitor: the transmembrane and cytoplasmic domains of tissue factor are not essential for the inhibitory action of tissue factor pathway inhibitor.
Kazama Y
Thromb Haemost; 1997 Mar; 77(3):492-7. PubMed ID: 9066000
[TBL] [Abstract][Full Text] [Related]
8. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
Burgering MJ; Orbons LP; van der Doelen A; Mulders J; Theunissen HJ; Grootenhuis PD; Bode W; Huber R; Stubbs MT
J Mol Biol; 1997 Jun; 269(3):395-407. PubMed ID: 9199408
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa.
Valentin S; Reutlingsperger CP; Nordfang O; Lindhout T
Thromb Haemost; 1995 Dec; 74(6):1478-85. PubMed ID: 8772224
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor.
Lindhout T; Franssen J; Willems G
Thromb Haemost; 1995 Sep; 74(3):910-5. PubMed ID: 8571320
[TBL] [Abstract][Full Text] [Related]
12. Recombinant tissue factor pathway inhibitor enhances the binding of factor Xa to human monocytes.
Li A; Chang AC; Peer GT; Wun TC; Taylor FB
Thromb Haemost; 2001 May; 85(5):830-6. PubMed ID: 11372676
[TBL] [Abstract][Full Text] [Related]
13. Effect of leukocyte proteinases on tissue factor pathway inhibitor.
Petersen LC; Bjørn SE; Nordfang O
Thromb Haemost; 1992 May; 67(5):537-41. PubMed ID: 1519213
[TBL] [Abstract][Full Text] [Related]
14. Factor Xa enhances the binding of tissue factor pathway inhibitor to acidic phospholipids.
Valentin S; Schousboe I
Thromb Haemost; 1996 May; 75(5):796-800. PubMed ID: 8725726
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant actions of tissue factor pathway inhibitor on tissue-factor-dependent plasma coagulation.
Ofosu FA
Semin Thromb Hemost; 1995; 21(2):240-4. PubMed ID: 7660146
[TBL] [Abstract][Full Text] [Related]
16. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies.
Nagase H; Enjyoji K; Kamikubo Y; Kitazato KT; Kitazato K; Saito H; Kato H
Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186
[TBL] [Abstract][Full Text] [Related]
17. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716
[TBL] [Abstract][Full Text] [Related]
18. Structure and biology of tissue factor pathway inhibitor.
Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
[TBL] [Abstract][Full Text] [Related]
19. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding.
Camire RM; Kalafatis M; Tracy PB
Biochemistry; 1998 Aug; 37(34):11896-906. PubMed ID: 9718313
[TBL] [Abstract][Full Text] [Related]
20. Protein S as cofactor for TFPI.
Hackeng TM; Rosing J
Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2015-20. PubMed ID: 19661488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
